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Abstract 
The second part of the Consensus Statement of the 
Italian Association of Hospital Gastroenterologists 
and Italian Society of Colo-Rectal Surgery reports on 
the treatment of chronic constipation and obstructed 
defecation. There is no evidence that increasing fluid 
intake and physical activity can relieve the symptoms 
of chronic constipation. Patients with normal-transit 
constipation should increase their fibre intake through 
their diet or with commercial fibre. Osmotic laxatives 
may be effective in patients who do not respond to 
fibre supplements. Stimulant laxatives should be re-
served for patients who do not respond to osmotic 
laxatives. Controlled trials have shown that serotonin-
ergic enterokinetic agents, such as prucalopride, and 
prosecretory agents, such as lubiprostone, are effec-
tive in the treatment of patients with chronic constipa-
tion. Surgery is sometimes necessary. Total colectomy 
with ileorectostomy may be considered in patients 
with slow-transit constipation and inertia coli who are 
resistant to medical therapy and who do not have 
defecatory disorders, generalised motility disorders or 
psychological disorders. Randomised controlled trials 
have established the efficacy of rehabilitative treat-
ment in dys-synergic defecation. Many surgical proce-
dures may be used to treat obstructed defecation in 
patients with acquired anatomical defects, but none is 
considered to be the gold standard. Surgery should be 
reserved for selected patients with an impaired quality 
of life. Obstructed defecation is often associated with 
pelvic organ prolapse. Surgery with the placement of 
prostheses is replacing fascial surgery in the treatment 
of pelvic organ prolapse, but the efficacy and safety of 
such procedures have not yet been established. 
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MEDICAL AND REHABILITATIVE 
TREATMENT
Behavioural modification is considered to be the first-line 
treatment in patients with symptomatic chronic constipa-
tion. If  the behavioural modification proves unsuccessful, 
various pharmacological approaches are available.  
Behavioural modification 
Recommendations for lifestyle changes in patients with 
chronic constipation are based on the widespread belief  
that constipation is associated with low physical activity, 
reluctance to defecate whenever the need is felt, and poor 
fluid intake.
Can behavioural changes help the patient with chronic 
constipation?
Physical exercise: Epidemiological studies report that 
constipation is more frequent in subjects with a seden-
tary lifestyle[1]. Physical activity can increase colonic tran-
sit time[2] and reduce other symptoms of  constipation in 
elderly subjects[3]. Trials evaluating the effect of  exercise 
in constipated patients are lacking. Increased physical 
activity is often recommended for patients with chronic 
constipation, but there is no evidence that constipation 
can be improved by increased physical activity.
Defecation habits: Patients with chronic constipation 
are often instructed to defecate when the need is felt 
and to try to defecate at the same time every day, ideally 
upon awakening and after meals, when the colonic motor 
activity is highest. This recommendation is based on the 
observation that many people with normal colonic activ-
ity routinely defecate at the same time each day[4]. Trials 
evaluating this recommendation in constipated patients 
are also lacking.
Increased fluid intake: It is generally believed that in-
creased fluid intake improves constipation. In one trial, 
healthy volunteers were given increasing amounts of  
liquids, up to 2 L/d. The volume of  urine increased, but 
the stool frequency did not[5]. This finding is not surpris-
ing because the absorption capacity of  the small intes-
tine is 7-10 L/d. Trials evaluating the effect of  increased 
liquid intake in constipated patients are lacking, and 
there is no evidence that constipation can be improved 
by increasing oral fluid intake, unless the patient is de-
hydrated[6]. Suggestions for behavioural changes are not 
usually helpful. These recommendations are supported 
by Level Ⅴ evidence, Grade C recommendation.
PHARMACOLOGICAL THERAPY 
Various drugs are available to treat chronic constipation 
(Table 1). Laxatives generally can resolve the symptoms 
of  constipation, but few rigorous studies on their effec-
tiveness have been conducted[7]. Placebo-controlled trials 
conducted over a sufficient period of  time are needed to 
demonstrate the actual efficacy of  an agent. Many trials 
have been of  short duration (4 wk), which limits the va-
lidity of  their conclusions because cognitive studies have 
shown that half  of  all patients become dissatisfied with 
their therapy over time[8]. Furthermore, the results of  
different studies are not always comparable; the defini-
tion of  constipation may not be sufficiently specific, and 
the therapeutic end-point may simply be stool frequency, 
without taking other symptoms into account. 
The resolution of  constipation-related symptoms is 
an important therapeutic target because constipation is 
a complex condition, with hard stool, straining, incom-
plete evacuation, bloating, and abdominal discomfort. 
Infrequent bowel movements are not always present, 
and infrequent bowel movements are certainly not the 
most unpleasant[8] symptom of  constipation. Addition-
ally, investigators have only recently begun to address 
the important problem of  quality of  life in patients with 
constipation, which has been shown to worsen as consti-
pation-related symptoms increase[9-11]. 
Defining constipation remains difficult[12]. Patients and 
physicians often have different feelings and opinions on 
the matter; patients use the word “constipation” to mean 
the annoying symptoms related to defecation, but physi-
cians use this term to describe infrequent bowel move-
ments[13,14]. Constipation has two different but overlapping 
pathophysiological characteristics: delayed transit and 
evacuation disorders. The Roma Ⅲ criteria[15,16] were devel-
oped by an international panel of  experts and have been 
applied in several clinical trials of  laxatives. These criteria 
have also been adopted in this consensus statement and 
are useful in clinical practice and for clinical research.   
Bulking laxatives
Bulking laxatives consist of  fibre. These agents must be 
ingested with sufficient amounts of  water to increase 
the weight of  the faeces. Their action begins within 12 
to 72 h, but their effectiveness should be assessed after a 
period of  some weeks. There are two types of  fibre: in-
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soluble and soluble. Insoluble fibre consists of  bran con-
taining cellulose, hemicellulose and lignin. Galattoman-
nan, pectin, gum and mucilage are types of  soluble fibre 
that can be found in fruits and in some vegetables. Most 
types of  soluble fibre are completely fermented in the 
colon, except psyllium, which is only partially fermented. 
Fermentation increases the production of  short-chain 
fats and gas; therefore, one side effect of  bulking laxa-
tives is bloating.
What evidence is there for the effectiveness of added 
fibre intake?
Current guidelines recommend the use of  fibre in both 
dietary and supplement form for the first-line treatment 
of  chronic constipation[17], but a recent review showed 
that there is little evidence to support this approach[18].
Trials of insoluble fibre
There have been only two well-conducted placebo-
controlled trials of  insoluble fibre[18]; the first used bran 
and the second used rye bread. The first trial was a 
crossover study that enrolled 24 patients. In this study, 
the effectiveness of  bran was documented only if  the 
placebo was given before the bran[19]. The second trial 
studied 29 patients and compared a diet rich in rye bread 
to a diet containing low-fibre bread. The bowel move-
ment frequency and difficulty in defecation significantly 
improved with a diet rich in rye bread[20]. 
In a randomised trial, 117 constipated patients were 
treated with bran plus water: one group was told to drink 
water as desired, whereas the other group was instructed 
to consume 2 L of  water per day. The ingestion of  bran 
plus 2 L of  water increased the stool frequency (P < 0.001) 
and reduced the use of  rescue laxatives[21]. Fibre supple-
mentation may lead to the increased use of  enemas and 
suppositories[22]. The data regarding insoluble fibre are 
conflicting[18]. Treating constipation with bran is sup-
ported by Level Ⅲ evidence, Grade C recommendation.
Trial of soluble fibre
Placebo-controlled trials of  psyllium: Psyllium fibre 
is partially soluble and is the most studied type of  fibre. 
Three placebo-controlled trials on the efficacy of  psyl-
lium have been published[23-25]. Two found that psyllium 
was superior to a placebo in increasing the frequency of  
defecation (P < 0.05) and improving the consistency of  
the stool (P < 0.05)[23,24]. Ashraf  et al[23] conducted a well-
designed study, but it only lasted 8 wk and only enrolled 
22 patients. The third study reported no significant dif-
ference between psyllium and a placebo[25].
Studies comparing psyllium with other laxatives: One 
trial reported no difference in the stool frequency be-
tween a regimen of  senna plus psyllium and psyllium 
alone[26]. A study comparing psyllium and laxatives (lact-
ulose, bisacodyl, docusate, senna and magnesium salts) 
found that psyllium was more effective in increasing the 
stool frequency and improving the stool’s consistency[27]. 
The use of  psyllium is supported by Level Ⅱ evidence, 
Grade B recommendation. 
Osmotic laxatives
Osmotic laxatives attract water into the colon by osmo-
sis. Sugar-based laxatives and polyethylene glycol (PEG) 
are effective after 24 to 48 h. Magnesium hydroxide and 
magnesium salts are effective after 6-8 h.
How effective are osmotic laxatives?
Placebo-controlled trials of  lactulose: Three trials 
have shown the effectiveness of  lactulose[28-30] in increas-
ing the stool frequency (P < 0.05). These trials may be 
biased, however, because of  the number of  patients en-
rolled and their age; furthermore, the sex distribution and 
treatment duration were not specified. The side effects of  
lactulose include bloating, nausea and abdominal cramps.
Trials of  lactulose vs  other laxatives: Several trials 
have compared lactulose with other laxatives. Lactulose 
was shown to be less effective than PEG[31,32]. Psyllium 
plus senna was shown to be more effective than lactulose, 
but this combination can cause incontinence[33-35]. No dif-
ference was found between lactulose and psyllium[36] or 
lactulose and sorbitol[37], but nausea was reported more 
frequently in patients treated with lactulose (P < 0.05)[37]. 
The recommendation regarding sorbitol could not be 
graded because of  insufficient data; the trial only en-
rolled men, and the randomisation procedure was not 
described[37]. The use of  lactulose is supported by Level 
Ⅱ evidence, Grade B recommendation.
Magnesium hydroxide and magnesium salts: There 
is only one study in the literature that compares magne-
sium hydroxide to bulking laxatives[38]. Published in 1987 
and focusing on elderly patients, this study has various 
drawbacks. However, in patients receiving magnesium 
hydroxide, the stool frequency was higher (P < 0.001), 
and the use of  rescue laxatives was lower (P < 0.01). 
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  Type of medication Drugs
  Laxatives
     Bulking (insoluble and 
     soluble fibres)
Bran, methylcellulose, psyllium 
     Osmotic Lactulose, sorbitol, magnesium hydrox-
ide, magnesium salts, polyethylene glycol
     Stimulant Anthraquinone derivatives: senna, aloe, 
cascara 
Diphenylmethane derivatives: bisacodyl, 
sodium picosulfate 
     Softening Liquid paraffin (vaseline oil), docusate, 
glycerine
  Serotoninergic enterokinetic 
  agents
Tegaserod, prucalopride, renzapride 
  Prosecretory agents Lubiprostone, linaclotide
  Gastrointestinal μ-opioid 
  antagonists
Methylnaltrexone, alvimopan
  Probiotics Bifidobacterium, lactobacillus
  Colchicine
Table 1  Classes of drugs used to treat chronic constipation
Bove A et al . Treatment of constipation and obstructed defecation
The possible risk of  hypermagnesemia with these agents 
must be mentioned[38]. Hypermagnesemia was not re-
ported in this study but can occur in patients suffering 
from renal disease[39]. 
No clinical trials using magnesium salts (Epsom salts, 
English salt) have been published in the last 40 years. 
The use of  magnesium hydroxide is supported by Level 
Ⅴ evidence, Grade C recommendation.
Placebo-controlled trial of  PEG: PEG is an organic 
polymer that is not degraded by the intestinal flora. The 
effectiveness of  PEG has been documented in numerous 
trials[40-44]. PEG increased the stool frequency (P < 0.01) 
while improving the stool consistency[40,41,43] and reduc-
ing other symptoms of  constipation[41,43]. Iso-osmotic or 
hypo-osmotic solutions of  PEG consistently improved 
the frequency of  bowel movements compared with the 
frequency before treatment (P < 0.001)[45]. PEG was well 
tolerated, and side effects (abdominal cramps, flatulence, 
nausea) were rare.  
Trials of  PEG vs  other laxatives: PEG is more effec-
tive than lactulose[31,32] in increasing the stool frequency 
and improving the stool’s consistency. In patients treated 
with PEG, there are also lower rates of  rescue medica-
tion use and flatulence. One trial showed that PEG was 
more effective than Tegaserod[46]. PEG is a pillar in the 
treatment of  chronic idiopathic constipation because 
of  its high efficacy. There is evidence that PEG pro-
vides significant benefits compared with placebos and 
other laxatives. Furthermore, retrospective studies show 
that PEG remains effective for up two years of  treat-
ment[46,47]. The use of  PEG is supported by Level I evi-
dence, Grade A recommendation.
Stimulant laxatives
Stimulant laxatives are not absorbed and have a proki-
netic effect in the colon; they stimulate the production 
of  secretions and reduce the absorption of  water and 
electrolytes. Stimulant laxatives begin to take effect 6 to 
12 h after administration. Bisacodyl and sodium picosul-
fate (SPS) are prodrugs[48].
How effective are the stimulant laxatives? 
Placebo-controlled trial of  stimulant laxatives: Al-
though stimulant laxatives have been used for many years 
to treat patients with constipation and are often used as 
rescue medications in clinical trials of  other laxatives, 
only recently have placebo-controlled trials of  stimulant 
laxatives been conducted. SPS[49] and oral bisacodyl[50] in-
crease the stool frequency (P < 0.0001) while improving 
the stool consistency and decreasing the symptoms of  
constipation and the use of  rescue medications (P < 0.01). 
These drugs are well tolerated and appear to generally 
improve the patient’s quality of  life.
Comparison of stimulant laxatives and other laxatives
Senna plus a bulk laxative[33,34] is more effective than lact-
ulose (P < 0.05) but less effective than psyllium alone[26]. 
The faeces are softer with lactulose than with stimulant 
laxatives (P < 0.001)[51].
Adverse effects of  stimulant laxatives include ab-
dominal cramps and diarrhoea. Experimental studies 
have shown that stimulant laxatives do not damage the 
colonic epithelium[52]. Hepatotoxicity has been reported 
with some products; anthraquinone derivatives can cause 
melanosis of  the colon.
Some physicians fear that the prolonged use of  
stimulant laxatives can induce dependency. The classi-
cal concept of  dependency to a drug is characterised 
by specific features such as lack of  control over intake, 
compulsive use and craving for the drug. The addiction 
to drugs usually occurs via the activation of  dopami-
nergic systems after passage through the blood-brain 
barrier. Stimulant laxatives are not absorbed and do not 
pass the blood-brain barrier, so there is no pharmaco-
logic basis for dependency. Moreover, the existence of  
“rebound constipation” after the laxatives are stopped 
has not been definitively established[6]. However, many 
constipated patients require a constant intake of  laxa-
tives to achieve normal (or what they believe to be 
“normal”) bowel movements. Additionally, the abuse of  
laxatives has been reported in some patients; these cases 
of  laxative misuse are often the result of  psychological/
psychiatric problems[53]. The use of  SPS and bisacodyl is 
supported by Level Ⅰ evidence, Grade B recommenda-
tion. It is not possible to provide graded recommenda-
tions for the other stimulant laxatives because placebo-
controlled trials are lacking. 
Softening laxatives
Softening laxatives make the stool softer by forming an 
emulsion of  the faeces with lipids and water. Olive oil and 
sweet almond oil can function as softeners if  their intake 
exceeds the absorptive capacity of  the small intestine.
What evidence is there for the effectiveness of softening 
laxatives?
Docusate: Docusate is an anionic detergent that mixes 
aqueous and fatty components, thereby softening the 
stool; it may be administered orally or rectally through 
enemas or micro-enemas. When administered per rec-
tum, docusate acts within 30 min.
Placebo-controlled trial of  docusate: Two trials test-
ing orally administered docusate yielded conflicting 
results. In the first trial, there was no difference in the 
stool frequency[54], but in the other study, a significant 
difference in stool frequency was observed (P < 0.01)[55].
Comparison of  docusate with other laxatives: Psyl-
lium was more effective than docusate for stool soften-
ing (P < 0.04)[56]. Therapy with docusate is supported by 
Level Ⅴ evidence, Grade C recommendation.
Liquid paraffin (vaseline oil): Liquid paraffin is taken 
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orally and begins to take effect 6-12 h after administra-
tion. It acts by reducing the absorption of  water and 
electrolytes. Its chronic use can damage the mucosal 
epithelium and lead to malabsorption of  fat-soluble vita-
mins; aspiration can cause lipoid pneumonia. We did not 
find any randomised clinical trials in the literature on this 
product.    
Glycerine: Glycerine, used as a suppository and mixed 
into enemas, is classified as a softening laxative, but its 
mechanism of  action is unclear. It is assumed that, ap-
plied locally, glycerine produces tissue dehydration and 
irritation that in turn stimulate contractions of  the rec-
tum and defecation.
Serotoninergic enterokinetic agents 
Serotonin (5-HT) is a critical component in the regula-
tion of  gut motility, visceral sensitivity, and intestinal se-
cretion. Serotonin acts mainly on the 5-HT3 and 5-HT4 
receptors expressed by enteric nervous system interneu-
rones. Stimulation of  the 5-HT4 receptor is responsible 
for excitatory effects such as the peristaltic reflex. 
The 5-HT4 receptor agonists belong to several dif-
ferent classes of  drugs. Cisapride is a substituted benza-
mide that acts as a partial 5-HT4 receptor agonist. Ren-
zapride is a benzamide hydrochloride that is a full ago-
nist of  the 5-HT4 receptor, an antagonist of  the 5-HT3 
receptor, and a weak partial antagonist of  the 5-HT2b 
receptor. Tegaserod is an aminoguanidineindole that is a 
5-HT4/5-HT1 receptor partial agonist and a 5-HT2 re-
ceptor antagonist. It also has been shown to inhibit do-
pamine and noradrenaline transporters. Prucalopride is a 
dihydrobenzofurancarboxamide that is a selective 5-HT4 
receptor agonist. 
What evidence is there for the effectiveness of these 
drugs? 
Placebo-controlled trials of  serotoninergic entero-
kinetic agents: A recent systematic review of  avail-
able controlled trials[57] showed that cisapride was more 
effective than a placebo in improving the gastroin-
testinal transit time. However, there was no evidence 
that cisapride use resulted in a global improvement of  
constipation-related symptoms compared to the placebo. 
It was concluded that cisapride use had no clear ben-
efit and that the use of  this drug could not be justified 
because of  its cardiotoxic side effects. Indeed, in 2000, 
cisapride was withdrawn from the market because it had 
been associated with rare dose-dependent cardiac events, 
including lengthening of  the QT interval, syncope, and 
ventricular arrhythmia in patients with predisposing con-
ditions. These effects may be caused by the interaction 
of  cisapride with the cardiac hER potassium channel. 
Although cisapride was withdrawn from the market, it 
can still be purchased online.
In a placebo-controlled trial, renzapride[58] was only 
marginally superior to a placebo in reducing the symp-
toms of  constipation and did not improve the quality of  
life. This drug  can cause ischemic colitis.
Large studies of  tegaserod[59-61] and prucalopride[62-65] 
have been conducted that enrolled over 2500 and 2000 
patients, respectively. Both drugs improved the stool 
frequency (P < 0.001), improved stool consistency, de-
creased the need for rescue medications, and reduced 
the symptoms of  constipation. Tegaserod was previously 
approved in the United States but was not approved in 
Europe, except in Switzerland. It was withdrawn from 
the market in March 2007 because of  an increased risk 
of  cardiovascular adverse events (including myocardial 
infarction, unstable angina, and stroke) and is now only 
available for emergency use. The cardiovascular side ef-
fects may be related to vasoconstriction mediated by 
5-HT1B receptors in the vascular wall[66]. 
Drugs with a higher selectivity for 5-HT4 receptors 
(e.g., prucalopride) may be able to minimise the inci-
dence of  cardiac side effects. In a small trial of  patients 
with chronic noncancer pain suffering from opioid-in-
duced constipation, prucalopride was found to be effec-
tive and safe[67]. The European Medicines Agency (EMA) 
approved the use of  prucalopride in July 2009. The use 
of  prucalopride is supported by Level Ⅰ evidence, Grade 
A recommendation.
Prosecretory agents 
Prosecretory agents stimulate the secretion of  fluid into 
the intestinal lumen by activating intestinal chloride 
channels (lubiprostone) or the guanylate-cyclase recep-
tors of  enterocytes (linaclotide). 
What evidence is there for the effectiveness of the 
prosecretory agents? 
Placebo-controlled trials using lubiprostone: Two tri-
als[68,69] showed that lubiprostone significantly increased 
the stool frequency, improved the stool consistency and 
reduced straining. Nausea was reported as a side effect. 
The Food and Drug Administration approved the use 
of  lubiprostone for the treatment of  adult patients with 
chronic idiopathic constipation in 2006. The EMA has 
not yet approved its use in Europe. The use of  lubipro-
stone is supported by Level Ⅰ evidence, Grade B recom-
mendation. 
Linaclotide: This drug has been reported to be effec-
tive in irritable bowel syndrome (IBS)[70]. In patients 
with chronic constipation[71,72], linaclotide significantly 
increased the stool frequency, improved the stool con-
sistency and reduced straining. The health-related quality 
of  life improved. Diarrhoea can be a side effect. The 
drug is currently being tested in a phase Ⅱ study.
Gastrointestinal μ-opioid receptor antagonists
Constipation is a side effect of  opioid treatment that re-
sults from interference with the gastrointestinal μ-opioid 
receptors. Methylnaltrexone and alvimopan can increase 
the intestinal motility in patients taking opioid medica-
tions (P < 0.001) without neutralising the analgesic effect 
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of  opioids[73-75]. 
One trial showed these drugs to be ineffective in pa-
tients with constipation-predominant IBS[76]. It therefore 
appears that gastrointestinal μ-opioid receptor antago-
nists are only effective against opioid-induced constipa-
tion. Level Ⅰ evidence, Grade A recommendation re-
garding the ineffectiveness of  this drug in patients with 
functional constipation.
Probiotics 
Probiotics are orally administered living microorganisms 
that can reach and colonise the bowel. They are mainly 
prescribed to reduce the bloating and abdominal pain 
that accompany IBS.
How effective are probiotics in the treatment of chronic 
constipation?
Milk fermented with Bifidobacterium lactis reduced the 
symptoms of  IBS but not constipation in 41 female IBS 
patients[77]. In women with “self-reported” constipation, 
probiotics reduced the severity of  constipation (P = 
0.003)[78]. Bifidobacterium animalis increased the stool fre-
quency (P < 0.01) and improved the stool consistency in 
both healthy and constipated women[79]. A study involv-
ing 28 subjects reported that Lactobacillus rhamnosus + 
Propiobacterium freudenreichii improved the stool frequency 
but did not decrease the consumption of  laxatives[80]. 
Placebo-controlled trials of  probiotics in chronic 
idiopathic constipation are lacking. Probiotics can be 
considered for use in conjunction with other drugs in 
the treatment of  chronic constipation. The use of  probi-
otics to treat chronic constipation is supported by Level 
Ⅴ evidence, Grade C recommendation.
Colchicine
Colchicine is effective in the treatment of  a variety of  
inflammatory syndromes. In two controlled trials that 
enrolled a total of  72 patients, colchicine increased the 
stool frequency and reduced the consumption of  laxa-
tives[81,82]. The use of  colchicine is supported by Level Ⅲ 
evidence, Grade C recommendation.
Procedures to empty the rectum and sigmoid colon
There is no controlled randomised trial in the literature 
addressing the chronic use of  suppositories or enemas, 
which are commonly used for relief  from occasional 
constipation and to empty the rectum in bedridden pa-
tients or those with impacted faeces. 
Suppositories act by making the stool softer and by 
generating a foreign body stimulus that leads to the def-
ecation reflex. The precise mechanism of  action of  trans-
anal irrigation is unknown. Its efficacy may be related to a 
wash-out effect, and large volumes of  liquid generate mass 
movements[83]. Irrigation volumes of  less than 100 mL do 
not produce distension of  the rectum. Without evacu-
ation, the liquid and its solutes are absorbed from the 
rectum.
Hyperphosphatemia has been reported as a serious 
adverse event following the misuse of  sodium phos-
phate enemas. A trial recently showed that transient mild 
hyperphosphatemia following the use of  sodium phos-
phate enemas correlates with retention time but not with 
dose[84].
Transanal irrigation of  the colon, with or without a 
rectal balloon catheter (Peristeen®), is a useful approach 
in patients with neurogenic bowel dysfunction secondary 
to spinal injury[85].
What is the evidence confirming the effectiveness of 
transanal irrigation in chronic constipation? 
Based on the rate of  colonic emptying, transanal irriga-
tion appears to be more effective in patients with spinal 
cord damage than in those with chronic constipation[85]. 
Retrospective studies report the benefits of  transanal 
irrigation for constipated patients. In one study of  16 
patients, symptoms were reduced in 19% of  patients 
suffering from constipation or obstructed defecation[86]. 
In another study of  37 patients, with a mean observation 
period of  4.5 years and a maximum observation period 
of  13 years, transanal irrigation was beneficial in 45% of  
patients with defecation disturbances[87]. Cazemier et al[88] 
consulted the database of  enterostomal therapists for 12 
patients for constipation and reported that after a mean 
observation period of  8.5 years, 42% of  patients rou-
tinely used transanal irrigation, and 60% were satisfied 
with this method. 
In patients with obstructed defecation, Gosselink et al[87] 
and Gardiner et al[89] reported, with colonic irrigation, an 
effectiveness of  65% and 57%, respectively. Recently, 
Christensen et al[90] presented the results of  a long-term 
study on Peristeen® and reported positive effects in 31% 
of  patients with slow transit constipation, in 43% of  
patients with obstructed defecation, and in no patients 
with indeterminate constipation. Retrograde irrigation 
for the treatment of  chronic constipation is supported 
by Level Ⅴ evidence, Grade C recommendation. Table 2 
summarises the levels of  evidence and the recommenda-
tion grade for various drugs.
At what point and on what grounds should we judge a 
treatment to be ineffective? 
Generally accepted criteria to define the response to medi-
cal therapy have not yet been developed. To date, every 
clinical trial has defined its own endpoints in terms of  the 
response to therapy. 
A medical treatment should be considered unsatis-
factory when a patient with good compliance does not 
report an appreciable improvement in the symptoms and 
quality of  life after at least 4 wk of  treatment at the full 
dose. To assess the therapeutic response, patients should 
be encouraged to keep a daily diary of  their symptoms[91].
REHABILITATIVE TREATMENT
Dys-synergic defecation can be effectively treated by re-
habilitative treatment (RT). Protocols vary among dif-
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ferent centres, but all RT programs aim to improve def-
ecation-related behaviour and restore a normal pattern 
of  defecation with both instruments and educational 
devices.
Electrostimulation, kinesitherapy, biofeedback and 
volumetric rehabilitation can be used in various combi-
nations to correct the dys-synergic behaviour of  abdom-
inal, rectal, and anal sphincter muscles and to improve 
rectal sensory perception.
RT requires a highly trained therapist and is time-
consuming both for the therapist and the patient. Pa-
tients must therefore be strongly motivated.
When should RT be prescribed for obstructed 
defecation?
Functional obstructed defecation is the main indica-
tion for RT. Biofeedback is the treatment of  choice for 
patients affected by pelvic floor dys-synergia. Three ran-
domised controlled trials[92-94] have shown a success rate 
of  approximately 70%[76] and a long-term success rate of  
approximately 50%[94]. Level Ⅰ evidence, Grade A recom-
mendation.
RT is also an effective therapy for organic diseases 
such as descending perineum syndrome, rectocele, recto-
anal intussusception, rectal mucosal prolapse, rectal 
solitary ulcer syndrome not related to rectal prolapse, 
and second-degree sigmoidocele[95,96]. Level Ⅳ evidence, 
Grade C recommendation. 
What is the recommended RT for obstructed defecation?
There are no universally accepted recommendations for 
RT, and there are no specific criteria to evaluate the ef-
ficacy of  this intervention. The methods used such as 
biofeedback, kinesitherapy, electrostimulation and volu-
metric rehabilitation can differ greatly, resulting in a con-
siderable variation in rehabilitation programmes among 
centres[97]. For this reason, the results of  different studies 
may not be comparable[98-100].
Biofeedback is a technique based on the use of  in-
struments to provide an information loop whose aim 
is to achieve operant conditioning[101]. Information on a 
physiological function (such as muscle contraction/relax-
ation) is translated into a visual or audio signal. When the 
execution of  a muscle movement is correct, a signal is ac-
tivated. Thus, erroneous functioning can be immediately 
corrected and the subject is conditioned to perform the 
correct contraction or relaxation movement. Some au-
thors have studied the use of  biofeedback combined with 
kinesitherapy for the pelvic and perineal muscles. The 
aim of  the therapy in this setting is to teach the patient 
the correct sequence of  contraction and relaxation of  
the striated muscles that is required for defecation[102-105]. 
It must be noted that these rehabilitative techniques have 
not been codified, they vary widely from one country to 
another, and they are supported by only one randomised 
trial[98]. Level Ⅱ evidence, Grade B recommendation.
RT may be useful for improving rectal sensation 
when anorectal manovolumetry demonstrates rectal hy-
posensitivity in patients with obstructed defecation[106]. 
Such RT may be performed through biofeedback (“sen-
sory retraining”)[107] or volumetric rehabilitation using an 
inflated balloon or water enemas of  decreasing volume 
and a probe to monitor muscle movement[108]. Neither 
biofeedback nor volumetric rehabilitation is supported 
by randomised controlled trials. Level Ⅳ evidence, Grade 
C recommendation.
Is RT the first therapeutic option?
Biofeedback, either alone or in combination with other 
rehabilitative techniques[102,103], is generally attempted 
only after pharmacological therapy has failed[95]. After 
drugs, however, rehabilitation is the treatment of  choice 
in patients affected by obstructed defecation because 
there are no side effects. Even if  RT fails, it will not have 
a deleterious effect on the patient’s condition, and its 
results will not affect future decisions regarding therapy, 
including surgery[106,108,109]. 
Is RT more effective than drug therapy?
One randomised trial showed that biofeedback was su-
Level of 
evidence
Grade of 
recommendation
  Life style 
     Physical exercise  Ⅴ C
     Toilet training Ⅴ C
     Increased fluid intake Ⅴ C
  Bulking laxatives  
     Insoluble fibre Ⅲ C
     Soluble fibre: Psyllium Ⅱ B
  Osmotic laxatives 
     Lactulose Ⅱ B
     Sorbitol Ⅴ C
     Magnesium hydroxide/magnesium salts Ⅴ C
     Polyethylene glycol Ⅰ A
  Stimulant laxatives 
     Sodium picosulfate, bisacodyl Ⅰ B
     Senna, aloe, cascara Ⅴ C
  Softening laxatives 
     Docusate Ⅴ C
  Serotoninergic enterokinetics 
     Tegaserod Ⅰ  A1
     Prucalopride Ⅰ A
  Prosecretory agents  
     Lubiprostone Ⅰ  B2
     Linaclotide   Ⅰ  B3
  Gastrointestinal μ-opioid antagonists 
     Methylnaltrexone Ⅰ(no effect) A (not used)
     Alvimopan Ⅰ(no effect)  A (not used)2
  Probiotics Ⅴ C
  Colchicine Ⅲ C
  Procedures to empty the rectum-sigma
     Peristeen® Ⅴ C
Table 2  Levels of evidence and grades of recommendation of 
medical treatment in chronic constipation
1Food and Drug Administration prescribing restrictions; 2Not approved in 
Europe; 3Phase Ⅱ study. Adapted from: American College of Gastroenter-
ology Chronic Constipation Task Force[184]; and Rao[249].
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cedure is to begin with RT[117] and, if  this proves inef-
fective, to then consider surgery[115]. Level Ⅱ evidence, 
Grade B recommendation. 
There are no clear guidelines to help the clinician 
decide between the approaches of  “rehabilitation-
surgery” and “rehabilitation-surgery-rehabilitation”. RT 
should certainly be prescribed if  the outcome of  ano-
rectal surgery is unsatisfactory[117]. In cases involving large 
rectoceles, anal fissures or severe anatomical anorectal 
changes, where it is unlikely that RT will have any direct 
effect, rehabilitative therapy should be prescribed after 
surgery[118]. Level Ⅴ evidence, Grade C recommendation. 
Concerning the efficacy of  RT following surgery, 
only a handful of  reports on patients who underwent 
RT for obstructed defecation after ano-rectal surgery 
have been published, each involving a different protocol. 
RT has been successful in treating persistent symptoms 
of  obstructed defecation after stapled trans-anal rectal 
resection (STARR)[119,120], hemorrhoidectomy, and sur-
gery for mucosal rectal prolapse[121]. Level Ⅴ evidence, 
Grade C recommendation. 
What are the medium- and long-term effects of RT? 
Lasting improvement has been observed in patients with 
dys-synergic defecation (confirmed clinically and by 
manometry) up to 2 years after RT[92,122-124]. LevelⅠ evi-
dence, Grade B recommendation.
SURGICAL TREATMENT FOR 
SLOW-TRANSIT CONSTIPATION
Colectomy
What are the conditions and selection criteria for 
colectomy?: There are no randomised trials focusing 
on the selection of  constipated patients for surgery. The 
most commonly described selection criteria for segmental, 
subtotal or total colectomy are (Level Ⅴ evidence, Grade 
C recommendation): (1) ≤ 2 weekly defecations[125-131]; 
(2) duration of  symptoms (mean 5-17 years)[130,132]; (3) 
the presence of  symptoms such as abdominal bloating or 
pain, nausea, and vomiting that have a significant impact 
on the patient’s quality of  life[110,113,130,132,117]; (4) failure of  
behavioural, dietetic, pharmacological and RTs to improve 
the symptoms[109-114,133]; (5) radiological evidence of  slow-
transit constipation[130,131,133-138]; (6) exclusion of  organic or 
functional pelvic floor disorders (obstructed defecation, 
Hirschsprung’s disease) based on defecography and ano-
rectal manometry[131,136-138]; (7) exclusion of  upper gastroin-
testinal tract dysmotility based on functional (manometric, 
scintigraphic) examinations, if  dyspeptic symptoms are 
present[137,139-141]; and (8) normal results of  psychological 
evaluation (patients with psychological disorders tend to 
show poor results after surgery for constipation)[136,142-145].
Total or subtotal colectomy with ileorectal anastomosis
What are the levels of  evidence and grades of  rec-
ommendation for this procedure?: No randomised 
or controlled studies have been published on this proce-
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perior to laxatives in improving defecation in patients 
affected by pelvic floor dys-synergia[97]. It should be 
noted that the laxative dosage was not high in the con-
trol group, but the finding remains that rehabilitation 
reduced the need for laxatives. Level Ⅰ evidence, Grade 
B recommendation. 
What factors may influence the efficacy of RT? 
There is no general agreement as to what factors may 
predict or influence the outcome of  RT[93,105,110]. In one 
study, no correlation was found between specific condi-
tions (rectocele, ano-rectal intussusception, descending 
perineum and sigmoidocele) and the efficacy of  bio-
feedback in patients with dys-synergic defecation[111]. 
Level Ⅳ evidence, Grade B recommendation. In a more 
recent study, harder stools, shorter duration of  laxative 
use, higher rectal pressure while straining and prolonged 
balloon expulsion independently predicted a positive 
outcome for RT[112]. Level Ⅲ evidence, Grade C recom-
mendation.
Nevertheless, significant anatomic damage, severe 
psychiatric or neurological disease, poor patient com-
pliance, and poor patient–physiotherapist interactions 
could pose major obstacles to the success of  RT[97,113]. 
Level Ⅲ evidence, Grade C recommendation.
Does surgery make RT superfluous? 
No, the experience suggests that RT, even if  it does not 
achieve satisfactory function, can improve pelvic floor 
muscle tone and coordination and can contribute sig-
nificantly to a positive outcome in ano-rectal surgery[114]. 
Level Ⅴ evidence, Grade C recommendation. 
How should patients who do not respond to RT be 
managed?
It is not clear how non-responsive patients should be 
managed because a validated, universally accepted set of  
criteria regarding the response to RT has not yet been 
developed. If  the clinical grounds for prescribing RT 
were appropriate (presence of  dys-synergic defecation 
and/or inadequate propulsive forces) and no negative 
predictive factors are present, the failure of  a patient to 
respond to RT should raise the suspicion of  significant 
organic damage (e.g., a rectocele or rectal intussuscep-
tion) and lead to the evaluation of  surgical options[115]. 
In fact, in patients with a rectocele and/or ano-rectal 
intussusception, one of  the prerequisites for surgery to 
correct obstructed defecation is the failure to respond to 
RT[115]. Level Ⅱ evidence, Grade C recommendation. 
In one report on a small number of  patients, sacral 
neuromodulation was found to be effective[116]. Level Ⅳ 
evidence, Grade C recommendation. 
Should RT be prescribed before or after ano-rectal 
surgery?
Although it is difficult to discriminate between patients 
who will derive some benefit from RT and those who 
instead will require surgery, the generally accepted pro-
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dure. Level Ⅴ evidence, Grade C recommendation. 
What is the success or satisfaction rate following 
surgery?: Definitive conclusions regarding the effective-
ness of  surgery cannot be drawn. The methods used to 
assess the outcome of  surgery and patient satisfaction 
vary greatly. Among 39 published studies, 6 did not define 
the criteria used, in 17 the assessment was based solely on 
patient feedback, and in 8 the conclusions were based on 
the results of  post-operative functional tests. Only in 8 
studies was the success of  surgery determined from func-
tional results and the patient’s evaluation. The data collec-
tion methods also differ between the studies; they were 
not defined in 15 of  the 39 studies reviewed, whereas a 
questionnaire was used in 15 studies; only in 9 studies was 
a post-operative interview conducted. The overall rate of  
success or satisfaction documented in 39 studies involving 
1423 patients was 86% (39%-100%)[125,129,130,133,136,146-149]. 
What are the post-operative morbidity and mortality 
rates?: The overall post-operative morbidity in 25 series 
was 20% (2%-71%)[125,129,130,134,149], and the mortality doc-
umented in 26 studies was 2.6% (0%-15%)[125,130,134,146]. 
Post-operative complications
What is the incidence of  small bowel obstruction, 
diarrhoea, faecal incontinence and abdominal pain, 
and what is the re-operation rate?: The complica-
tion rates were (mean and range): (1) small bowel ob-
struction, evaluated in 26 series with 913 patients: 18% 
(2%-71%)[125,129,130,134,146]; (2) chronic diarrhoea, in 19 series 
with 843 patients: 14% (0%-46%)[130,136,146,148]; (3) faecal 
incontinence, in 21 series with 913 patients: 15% (0%-52%)
[125,129,130,136,146,148]; (4) abdominal pain, in 19 series with 839 
patients: 35% (0%-90%)[125,129,130,136,143,146,148]; and (5) re-
operation rate, evaluated in 5 studies with 965 patients: 
14% (0%-50%)[125,130,134,149]. 
What are the functional results after surgery, in 
terms of  daily bowel movement rates and recurrent 
constipation?: In 26 studies[125,129,130,133,146,148] involving 
1047 patients and with a mean follow-up period of  44.8 
(12-180) mo, the rate of  bowel movements reported by 
the patients was 2.8 times per day, whereas recurrent 
constipation was reported by 9% (0%-33%) of  683 pa-
tients in 17 series[129,130,136].
How often is a permanent stoma the only solution for 
a patient?: The incidence of  permanent stoma place-
ment as a therapy of  last resort was 5% (0%-28%) in 27 
studies involving 930 patients[125,130,150].  
What prognostic factors have been identified?: Pre-
servation of  the ileocaecal valve and caecum during 
isoperistaltic anastomosis resulted in a higher rate of  
persistent or recurrent constipation[145,146,150,151]. One 
controlled study[146] reported better results in 45 patients 
who underwent ileosigmoid anastomosis compared with 
34 patients who underwent isoperistaltic caecorectal 
anastomosis (93% vs 73%). Level Ⅲ evidence, Grade C 
recommendation. (1) Negative prognostic factors de-
scribed in the literature include the onset of  constipation 
in adulthood or after pelvic or intestinal surgery[151-153]; (2) 
Positive prognostic factors include childhood onset and 
“lifelong” duration of  symptoms[154,155]. 
Is autonomic neuropathy an indication for surgery?: 
A higher rate of  post-operative complications (especially 
small bowel obstruction) and the persistence of  pre-
operative symptoms (abdominal pain and bloating) have 
been reported in patients with autonomic neuropathy[141]. 
Therefore, some authors consider autonomic neuropathy 
to be a contraindication to surgery[138]. Level Ⅴ evidence, 
Grade C recommendation. 
Can laparoscopy yield better results than surgery?: 
Four studies without controls and one evaluating a 
“hand-assisted” technique have been published, but 
these were primarily feasibility studies[129,134,136,156,157]. 
Segmental colectomy
Can segmental colectomy lead to better function-
ing?: It appears that if  the decision to undertake seg-
mental colectomy is based on radiologically demon-
strated segmental colonic slow transit, good results can 
be achieved in 82%-96% of  patients[136,158,159]. Without 
this evaluation, the failure rate is 100%[151,160]. Level Ⅴ 
evidence, Grade C recommendation. 
Subtotal colectomy with antiperistaltic 
caecoproctostomy (Sarli’s procedure)
Can this procedure lead to better results than con-
ventional total or subtotal colectomy?: In the lit-
erature, 3 series[126,157,161] have reported on a total of  43 
patients in whom a subtotal colectomy with caecal pres-
ervation and antiperistaltic cecorectal anastomosis was 
performed. These were non-randomised but controlled 
studies, with subjects undergoing ileorectal anastomosis. 
Level Ⅲ evidence, Grade C recommendation. Patients 
reported less faecal incontinence (documented by the 
Wexner score), less use of  anti-diarrhoeal drugs, fewer 
defecations per day, more consistent faeces and a better 
quality of  life after surgery. After 4.5 years (range 2-7) of  
follow-up, the mean daily number of  bowel movements 
was 2.5, and the success rate of  the surgical procedure 
was 88% (65% in patients with ileorectal anastomosis).   
Does this procedure have a lower incidence of  com-
plications?: The cumulative post-operative complication 
rate was 9% (in 22 patients); 2 (1%) patients experienced 
small bowel obstruction, but none complained of  diar-
rhoea[126,157,161].     
Malone antegrade continence enema 
What patients are candidates for this procedure?: 
Although good results have been reported recently in 
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adults, Malone antegrade continence enema (MACE) is 
most successful in paediatric patients[162,163] or in patients 
with neurological diseases such as myelomeningocele, 
cerebral or spinal cord injuries, or Hirschsprung’s dis-
ease[163-169]. The greatest improvement in the quality of  
life was observed in patients with concomitant faecal 
incontinence[168]. Level Ⅴ evidence, Grade C recommen-
dation. 
What is the level of  evidence and recommendation 
grade for this procedure?: The level of  evidence and 
recommendation grade cannot be determined because 
there are no randomised or controlled studies on MACE 
in the literature[162-172]. 
What is the success or satisfaction rate with the Ma-
lone procedure?: The methods of  assessing the overall 
success or satisfaction rate vary widely among studies. 
Among 7 studies, the criteria were not clearly defined 
in one, success/satisfaction was based on the patient’s 
judgement in another, and in 5 the outcome was evalu-
ated based on functional results and the patient's judge-
ment. The data collection methods also varied; they 
were based on a questionnaire and interview in 4 studies, 
whereas an interview was conducted in only 3 studies. 
With a mean follow-up period of  44 (range 12-78) mo, 
the overall success or satisfaction rate, documented in 7 
studies on 67 patients, was 74% (50%-100%)[164-166,169-172], 
but within 3 years, the MACE procedure was replaced 
by other therapies in 50%-75% of  cases[165,171]. 
What complications have been observed?: The main 
complication of  this procedure is stenosis of  the stoma 
(8%-50%)[163,165,166,169-171].
Sacral nerve stimulation 
What is the level of  evidence and the recommenda-
tion grade for this procedure in patients with con-
stipation?: One double-blinded, placebo-controlled 
crossover study in 2 patients[173] and 7 non-randomised 
studies[116,174-179] have been published, but 3 of  these stud-
ies[173-175] probably used the same patients. One of  these 
trials was presented only in the form of  an abstract at 
Digestive Diseases Week in 2007[177] and for this reason 
was not taken into consideration in the calculation of  
the mean success rate. In this report by Kamm et al[177], 
the success rate of  a temporary implant was 66% (n = 
67), and all patients with a permanent implant continued 
to show good results after 12 mo of  follow-up. 
In a recent prospective study at five European sites, 
sacral nerve stimulation (SNS) was effective among pa-
tients with idiopathic slow and normal transit constipa-
tion resistant to conservative treatment. The primary end 
points were increased defecation frequency, decreased 
straining and decreased sensation of  incomplete evacua-
tion (P < 0.001)[179] (Level Ⅲ evidence, Grade C recom-
mendation).    
What is the mean success rate of  percutaneous nerve 
evaluation followed, if  indicated, by the insertion of  
a permanent pacemaker?: The overall success rate of  
percutaneous nerve evaluation, as documented in 4 stud-
ies involving 86 patients, was 60% (25%-75%)[174,176,177,179]. 
In 2 studies[116,173] involving a total of  12 patients who re-
ceived permanent pacemakers, the reported success rates 
were 100% and 75% after a median follow-up of  11 and 
8 mo, respectively. Finally, the multicentre prospective 
study coordinated by Kamm et al[179] reported that after a 
median of  28 mo (range 1-55), the frequency of  defeca-
tions increased from a baseline of  2.3 evacuations per 
week to 6.6 evacuations per week. 
SURGERY FOR OBSTRUCTED 
DEFECATION
The management of  patients affected by obstructed def-
ecation can be challenging because of  the frequent as-
sociation of  anatomical and functional anomalies, which 
makes it difficult to distinguish between the causes and 
consequences of  excessive strain[180,181]. The complexity 
of  the syndrome and the range of  available treatments 
make the outcome of  the therapy unpredictable[182]. 
Surgery is usually considered for patients with reparable 
anatomical defects, concomitant pathologies, or symp-
toms that severely impact their quality of  life[183]. 
Indications for surgery in constipation arising from 
obstructed defecation
Surgical treatment is indicated in cases of  reparable ana-
tomical defects, severe symptoms, symptoms leading to a 
poorer quality of  life, or concomitant pathologies[183,184]. 
Level Ⅴ evidence, Grade C recommendation.
What criteria are there for evaluating treatment efficacy 
(severity score, defecography, quality of life)?
The obstructed defecation syndrome (ODS) score is a 
tool designed to evaluate patients suffering from pure 
outlet obstruction without slow transit or mixed forms 
of  constipation. The ODS provides an index of  the 
disease severity and can be used to monitor the efficacy 
of  therapy[182]. Level Ⅲ evidence, Grade C recommen-
dation. Other tools, such as the Constipation Scoring 
System[185] and the KESS Score[186], are not specific for 
ODS but can be employed to study other forms of  con-
stipation; some items in these scores are not influenced 
by the therapy[185].
There are two approaches - abdominal (rectopexy) 
and trans-anal (STARR or Delorme transrectal excision) 
- to surgically correct internal intussusception: Which is 
recommended on the basis of  the clinical evidence?
The results of  rectopexy are uncertain. Some studies 
report the persistence or worsening of  constipation and 
difficulty in emptying the rectum in approximately 50% 
of  cases, although the prolapse is corrected in almost all 
patients[187]. Other studies report that resection and rec-
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topexy improve the symptoms relating to intussuscep-
tion and coexisting anatomical and functional patholo-
gies of  the pelvic floor, such as enterocele, solitary ulcer 
of  the rectum, incontinence and descending perineum 
syndrome[188]. Level Ⅴ evidence, Grade C recommenda-
tion. 
Colonic resection and rectopexy can reduce intussus-
ception in 100% of  cases, restore anal muscle tone (P = 
0.002), reduce the descending perineum (P < 0.001) and 
accelerate colonic transit (P < 0.001) with stable results 
over time (based on a 5-year follow-up)[188]. Level Ⅴ evi-
dence, Grade C recommendation. 
Sutureless rectal mobilisation, suture rectopexy, and 
mesh rectopexy: Which is better? 
In a multicenter randomised study of  252 patients, an 
actuarial analysis demonstrated a significant difference in 
5-year recurrence rates between no-rectopexy and rec-
topexy groups (8.6% vs 1.5%) (log-rank, P = 0.003)[189]. 
Level Ⅴ evidence, Grade C recommendation.
A ventral instead of  posterior mobilisation and fixa-
tion of  the mesh have recently been advocated and 
popularised. Excellent results have been claimed, but no 
randomised comparative trials have been conducted thus 
far[190-193]. Level Ⅴ evidence, Grade C recommendation.
Laparoscopy or laparotomy for rectopexy?
Although there are no studies comparing the two differ-
ent approaches, there is a tendency in the literature to 
perform this operation laparoscopically because of  the 
potential of  this approach to shorten hospital stays, de-
crease the incidence of  abdominal wound complications 
and improve cosmesis.
A trial assessed the quality of  life in ODS patients 
comparing STARR with biofeedback and reported that 
the STARR was better (P < 0.0001)[115]. Level Ⅱ evi-
dence, Grade C recommendation.
Which approaches to repair a rectocele (trans-anal, 
trans-vaginal, perineal, etc.) can be recommended on 
the basis of evidence based medicine?
The indications for surgery and the choice of  pro-
cedure are still being debated, and a clear correlation 
between the correction of  the anatomical problem and 
the improvement of  symptoms has not yet been dem-
onstrated[194]. Surgery should only be considered when 
conservative therapy has failed. Options include trans-
vaginal posterior colporraphy and trans-rectal or trans-
perineal repair[183]. In terms of  an improvement in symp-
toms, Arnold et al[195] did not find any difference between 
the trans-anal and the trans-vaginal approaches. Level 
Ⅴ evidence, Grade C recommendation. Even when the 
surgical repair has been correctly performed, 30%-72% 
of  patients still experience difficulties in defecating[196]. 
Level Ⅴ evidence, Grade C recommendation. Post-
surgical complications include faecal incontinence and 
sexual dysfunction[197,198]. 
Is there a technique that can be considered the gold 
standard for the treatment of ODS?
Numerous surgical procedures using different approach-
es (abdominal, vaginal, trans-anal or perineal) are avail-
able for the treatment of  ODS, but none has been iden-
tified as the gold standard[115]. Level Ⅱ evidence, Grade 
B recommendation.
Can obstructed defecation resulting from rectocele/
intussusception also be associated with slow-transit 
constipation?
Slow colonic transit is often observed in patients with 
a symptomatic rectocele[198,199]. The obstructed defeca-
tion in these patients does not appear to exclusively 
result from the rectocele (Level Ⅴ evidence). Although 
improved rectal emptying may be observed after surgi-
cal correction, this effect is not likely to affect colonic 
function. It has been demonstrated that patients with 
poor functioning after repair of  the rectocele still have a 
prolonged colonic transit time[200]. Furthermore, patients 
with a slow transit time before the operation show little 
improvement after surgery[198] (Level Ⅴ evidence).
Can STARR be effective in the treatment of patients with 
ODS who fail to respond to medical and RT?
The efficacy and safety of  STARR has been demonstrat-
ed in ODS patients in whom 5-10 sessions of  biofeed-
back therapy (BF) failed[115]. Level Ⅱ evidence, Grade 
B recommendation. This study showed a reduction of  
the ODS score in 81.5% of  patients after STARR (one-
year follow-up) compared with a reduction of  13% after 
BF (difference between the two groups: 48.1%, P < 
0.0001, 95% CI: 30.1%-66.2%). This study had several 
drawbacks, however, including the small number of  par-
ticipants enrolled, a 50% dropout rate in the BF group, 
and the fact that a surgical approach was compared with 
a non-surgical one.
Can STARR improve the quality of life in patients with 
rectal intussusception or a rectocele? 
The STARR procedure can significantly improve the 
quality of  life in patients suffering from ODS arising 
from rectal intussusception or a rectocele compared with 
biofeedback (P < 0.0001)[115]. However, other options, 
such as pelvic floor rehabilitation or the internal Delor-
me procedure[201], could be considered instead to prevent 
any potential risk associated with the stapling procedure. 
Level Ⅱ evidence, Grade B recommendation.
In cases of ODS arising from rectal intussusception or 
rectocele, can stapled trans-anal prolapsectomy with 
perineal levatorplasty alleviate the symptoms?
Boccasanta et al[202] compared the stapled trans-anal pro-
lapsectomy with perineal levatorplasty (STAPL) and 
STARR procedures in a randomised trial. All of  the 
symptoms relating to obstructed defecation improved 
following both procedures. After a 20-mo follow-up, the 
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results were still good in 76% of  the STAPL patients 
and in 88% of  the STARR patients. The authors none-
theless concluded that STARR is preferable because 
of  the lower post-operative pain (P < 0.001), reduced 
rectal sensitivity (P < 0.017), absence of  dyspareunia (P 
< 0.018), and a more marked reduction in the rectocele. 
Level Ⅰ evidence, Grade B recommendation.
What procedure should be performed in cases of 
complete rectal prolapse?
Abdominal rectopexy with sigmoidectomy and plain rec-
topexy with mesh are safe and effective procedures for 
the treatment of  complete rectal prolapse[202]. Level Ⅱ 
evidence, Grade B recommendation. Only one prospec-
tive randomised trial has compared abdominal rectopexy 
and sigmoidectomy (group Ⅰ ) with rectopexy and a 
polyglycolic acid mesh (group Ⅱ). After correction of  
the prolapse, 8/11 patients in group Ⅰ suffering from in-
continence and 10/12 in group Ⅱ who had incontinence 
improved. Six months after surgery, the constipation had 
disappeared in 3 and 7 patients from groups Ⅰ and Ⅱ, 
respectively, but 5 other patients from group Ⅱ required 
a colectomy within one year after the operation because 
of  severe constipation[203].
Is abdominal rectopexy with sigmoidectomy associat-
ed with higher rates of  morbidity than simple rectopexy 
in patients with complete rectal prolapse? Should this 
procedure be performed in cases of  slow transit consti-
pation or only in patients with dolicocolon?
Sigmoid resection with rectopexy is effective in re-
ducing post-operative constipation arising from outlet 
obstruction without increasing the rate of  morbidity[201]. 
Level Ⅱ evidence, Grade B recommendation. Rectopexy 
with sigmoid resection can improve the colonic transit (P 
< 0.001)[196], even in the presence of  dolicocolon (Level 
Ⅴ evidence, Grade C recommendation).
Is SNS effective for the treatment of patients with ODS 
constipation?
SNS may be effective in the treatment of  chronic consti-
pation when other approaches have failed[204]. In a recent 
prospective study at five European sites, SNS was effec-
tive in patients with idiopathic slow and normal transit 
constipation who failed conservative treatment. In this 
study, the primary end points were increased defecation 
frequency, decreased straining and decreased sensation 
of  incomplete evacuation (P < 0.001)[179] (Level Ⅲ evi-
dence, Grade C recommendation).     
When surgery is indicated for solitary rectal ulcer 
syndrome, what procedure should be adopted?
Solitary rectal ulcer may be associated with paradoxical 
contraction of  the puborectal muscle, recto-anal intus-
susception, rectal prolapse and descending perineum 
syndrome. Treatment of  this condition must be conser-
vative. Surgery can be considered for patients with full-
thickness rectal prolapse or intractable haemorrhage, but 
the degree of  continence and constipation and the risks 
of  surgery must be carefully assessed in each individual 
patient, and the patient’s preferences regarding treatment 
should be taken into account. The procedure selected 
must be safe and balance the risk of  morbidity with an ac-
ceptable recurrence rate[183,205,206]. Level Ⅴ evidence, Grade 
C recommendation. The surgical options include repair 
of  the rectal prolapse with or without resection of  the 
lesion, although the long-term results of  this procedure 
were found to be uncertain. Anterior resection and proc-
tocolectomy have shown satisfactory long-term results[207].
When is surgery indicated for sigmoidocele?
Surgery is indicated for symptomatic patients with third-
degree sigmoidocele (below the ischiococcygeal line) 
or patients who require other pelvic surgery with an 
abdominal or vaginal approach (hysterectomy, rectal pro-
lapse, rectocele repair). The surgery consists of  sigmoid 
resection and rectopexy with obliteration of  the Douglas 
pouch. Jorge et al[208] documented an improvement of  the 
symptoms in 100% of  patients undergoing this proce-
dure, compared with 33% of  patients who were treated 
conservatively, after a mean follow-up of  33 mo. Level 
Ⅴ evidence, Grade C recommendation.
What is the best surgical treatment for megarectum with 
or without megacolon?
There has been considerable debate regarding the sur-
gical treatment for megarectum. In megarectum with 
megacolon, colectomy and ileo-rectal anastomosis is the 
procedure with the best functional results and the lowest 
morbidity[209]. In patients who do not experience satisfac-
tory results, total proctocolectomy and ileo-pouch-anal 
anastomosis is the treatment of  choice to avoid perma-
nent ileostomy[210,211] (Level Ⅴ evidence). In idiopathic 
megarectum, proctectomy and colo-anal anastomosis 
with or without colonic reservoir has shown good re-
sults; defecation and faecal continence were satisfactory 
in 72% of  patients[212,213] (Level Ⅴ evidence). The Du-
hamel procedure is less successful for the treatment of  
idiopathic megarectum than for Hirschsprung’s disease[214]. 
In idiopathic megarectum, this procedure is associated 
with the persistence of  symptoms and often with the 
need for a repeat operation[215]. It has been reported that 
rectoplasty with vertical reduction of  the rectum and 
sigmoid resection results in a significant improvement in 
the frequency of  defecation, a reduced consumption of  
laxatives or enemas, and satisfaction with surgery in 83% 
of  the patients[216] (Level V evidence, Grade C recom-
mendation).
SURGERY FOR OBSTRUCTED 
DEFECATION WITH ASSOCIATED PELVIC 
DISEASES
How often is obstructed defecation associated with 
pelvic organ prolapse?
A posterior colpocele in pelvic organ prolapse (POP) 
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may be linked to anatomical conditions such as a recto-
cele, enterocele or sigmoidocele[217]. Of  POP patients, 
24%-52% complain of  difficulties in defecation[218]. 
Straining is more common in women with prolapse (61% 
vs 4%; P < 0.001)[219].
 
Is there a correlation between POP and chronic 
constipation?
The literature is sparse on this point. In a study of  302 
patients with urinary incontinence and/or POP, Jelovsek 
et al[220] concluded that chronic constipation plays no sig-
nificant role in the etiology of  the prolapse (Level Ⅳ evi-
dence). Soligo et al[221] found that the prevalence of  con-
stipation was 33% (95% with obstructed defecation) in 
786 women suffering from uro-gynecologic dysfunctions. 
A significant correlation was noted between constipation 
and posterior genital prolapse (Level Ⅳ evidence). Similar 
data have been reported by other authors[222-224]. 
How does the physiopathologic correlation between 
POP and obstructed defecation contribute to posterior 
colpocele and rectocele?
At present we do not know whether constipation is a 
symptom caused by anatomic functional defects of  the 
pelvic floor[221], or whether it is the cause of  static and 
dynamic changes in the pelvis. Pudendal neuropathy 
arising from stretching of  the pudendal nerve while 
straining in patients with chronic constipation[225] (Level 
Ⅲ evidence) may explain the prolapse of  the posterior 
wall and the overall weakening of  the pelvic floor[226,227] 
(Level Ⅳ evidence). According to DeLancey[226], the ton-
ic contraction of  the levator ani, the perineal membrane 
and the endopelvic fascia provide the main support for 
the posterior vaginal wall. Under physiologic condi-
tions, the levator ani has a double vector. The muscle 
exerts forward force (closing the vaginal walls) and then 
extends downward to the perineal body, supported by 
the perineal membrane, which anteriorly is anchored to 
the ischiopubic branches. This compensating balance 
eliminates any traction on the endopelvic fascia (corre-
sponding to the middle third of  the vagina or DeLancey 
level Ⅱ). Pudendal neuropathy reduces the strength of  
the levator ani, and the downward vector will tend to be 
toward the posterior vaginal wall rather than the perineal 
body. A weak endopelvic fascia leads to posterior vaginal 
wall prolapsed, which may explain both the high and low 
rectoceles involving the middle vagina and the perineal 
body, respectively. 
What are the most recent anatomical and functional 
developments in pelvic reconstructive surgery?
Increasingly, prostheses are replacing fascial surgery in 
the treatment of  POP. The synthetic prosthesis is set 
in a tension-free position and connected to structures 
such as the obturator membrane, the arcus tendineous 
of  the pelvic fascia, the sacrospinous ligaments or the 
perineal body. The use of  a synthetic mesh has resulted 
in a marked decrease in recurrence (from 29% in fascial 
reconstructions to 9% with synthetic mesh), and a signif-
icant increase in erosion from 0.7% with the re-absorb-
able mesh to 10.2% with the synthetic mesh[228] has been 
observed. Level Ⅱ evidence, Grade B recommendation. 
However, the efficacy and safety of  the prostheses used 
for the posterior vaginal wall have not yet been estab-
lished[228] (Level Ⅱ evidence).  
Surgical treatment for rectocele has been evaluated 
in 4 randomised studies (Cochrane Review, 2007[229-233]. 
The transvaginal approach was associated with the low-
est number of  recurrences, the use of  biologic prosthe-
ses did not reduce the recurrence rate, and there was 
no significant difference between trans-anal and trans-
vaginal procedures in terms of  effects on defecation. 
Level Ⅰ evidence, Grade A recommendation. 
Does obstructed defecation improve after the correction 
of a posterior colpocele with mesh?   
Few studies have considered the effect of  surgery for 
posterior colpocele on posterior compartment dysfunc-
tion. The improvement reported in 24%-28%[234,235] of  
cases in two studies was not based on an adequate scor-
ing system (Level Ⅴ evidence). The presumption that a 
dysfunction such as constipation can be treated simply 
by correcting an anatomic defect is probably incorrect. 
Approximately 30% of  patients with obstructed defeca-
tion also complain of  slow-transit constipation[236] (Level 
Ⅴ evidence). We do not yet understand the pathophysi-
ology of  these conditions, particularly with respect to 
the role of  the CNS and ENS. The severity of  the ob-
structed defecation is also not correlated with the results 
of  the pelvic organ prolapse quantification[237-239] or to 
the anatomic-functional data provided by defecogra-
phy[222] (Level Ⅴ evidence, Grade C recommendation).
What is the recommended surgical procedure for 
post-hysterectomy voltocele?
Voltocele affects 18.2% of  women with genital prolapse 
after hysterectomy. In 72% of  these patients, there is also 
an anterior (cystocele) or posterior colpocele (rectocele 
or enterocele)[240,241]. The incidence of  enteroceles after 
hysterectomy is between 0.1% and 16%[242]. Voltocele 
is caused by damage to the supporting uterosacral and 
cardinal ligaments. Enterocele, a herniation of  the Doug-
las pouch between the vagina and the rectum, is caused 
by damage to the perineal membrane, which supports 
the posterior vaginal wall and connects the ischiopubic 
branches to the perineal body (Level Ⅴ evidence)[243,244]. 
The levator ani muscle is also important because it is 
connected to the middle of  the vagina by the endopelvic 
fascia. Three procedures designed to prevent enterocele 
and posterior colpocele after hysterectomy, i.e., the Mos-
chcowitz method, the McCall method, and simple closure 
of  the Douglas pouch, were compared in a prospective 
randomised study with 3 years of  follow-up, and the best 
results were obtained with the McCall operation[245] (Level 
Ⅱ evidence, Grade B recommendation). 
Many techniques have been proposed to correct a 
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voltocele associated with an enterocele. The abdominal 
approach with mesh sacrocolpopexy and Douglas oblit-
eration repairs the anatomic defect in 90% of  cases[246-248]. 
In a Cochrane review of  22 controlled randomised stud-
ies, abdominal sacrocolpopexy appeared to be superior to 
the transvaginal approach (vault sacrospinous fixation), 
with fewer recurrences and less dyspareunia[229], but it is a 
longer and more painful procedure that involves a longer 
hospital stay and higher costs[241]. Level Ⅰ evidence, Grade 
A recommendation. No data are available on the effects 
of  these procedures on constipation.
APPENDIX
This paper is the second part of  the consensus state-
ment of  the AIGO/SICCR regarding the diagnosis and 
treatment of  chronic constipation and obstructed def-
ecation. This section will focus on the treatment of  this 
condition.
The first part of  the paper was published in the World 
Journal of  Gastroenterology 2012 April 14 (ISSN 1007-9327) 
and describes the materials and methods used to gener-
ate these recommendations. Similar to that paper, this 
article presents the results in a “question-and-answer” 
format.
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